CL2024002361A1 - Anticuerpos terapéuticos - Google Patents
Anticuerpos terapéuticosInfo
- Publication number
- CL2024002361A1 CL2024002361A1 CL2024002361A CL2024002361A CL2024002361A1 CL 2024002361 A1 CL2024002361 A1 CL 2024002361A1 CL 2024002361 A CL2024002361 A CL 2024002361A CL 2024002361 A CL2024002361 A CL 2024002361A CL 2024002361 A1 CL2024002361 A1 CL 2024002361A1
- Authority
- CL
- Chile
- Prior art keywords
- therapeutic antibodies
- antibodies
- eczema
- modulate
- signal transduction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB202201674 | 2022-02-09 | ||
| GBGB2209454.4A GB202209454D0 (en) | 2022-06-28 | 2022-06-28 | Therapeutic antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002361A1 true CL2024002361A1 (es) | 2024-11-29 |
Family
ID=85283675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002361A CL2024002361A1 (es) | 2022-02-09 | 2024-08-07 | Anticuerpos terapéuticos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250340659A1 (enExample) |
| EP (1) | EP4476256A1 (enExample) |
| JP (1) | JP2025506488A (enExample) |
| KR (1) | KR20240139085A (enExample) |
| AU (1) | AU2023219227A1 (enExample) |
| CA (1) | CA3258958A1 (enExample) |
| CL (1) | CL2024002361A1 (enExample) |
| CO (1) | CO2024010901A2 (enExample) |
| IL (1) | IL314314A (enExample) |
| MX (1) | MX2024009898A (enExample) |
| WO (1) | WO2023152486A1 (enExample) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| AU2005229009A1 (en) * | 2004-03-23 | 2005-10-13 | Amgen, Inc. | Monoclonal antibodies specific for human OX40L (CD 134L) |
| US7812133B2 (en) * | 2005-12-16 | 2010-10-12 | Genentech, Inc | Anti-OX40L antibodies and methods using same |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| HRP20180858T1 (hr) | 2011-07-11 | 2018-09-21 | Glenmark Pharmaceuticals S.A. | Protutijela koja se vežu na ox40 i njihove uporabe |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| AU2013221502C1 (en) * | 2012-02-14 | 2018-03-01 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| KR102740384B1 (ko) | 2015-03-03 | 2024-12-06 | 키맵 리미티드 | 항체, 용도 및 방법 |
| GB2561352B (en) | 2017-04-10 | 2023-01-18 | Genome Res Ltd | Animal models and therapeutic molecules |
| KR20250026872A (ko) | 2018-03-16 | 2025-02-25 | 조에티스 서비시즈 엘엘씨 | 수의학적 용도를 위한 인터류킨-31 단클론성 항체 |
| GB2578867A (en) | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
| GB202012331D0 (en) * | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
-
2023
- 2023-02-08 IL IL314314A patent/IL314314A/en unknown
- 2023-02-08 JP JP2024547510A patent/JP2025506488A/ja active Pending
- 2023-02-08 KR KR1020247029746A patent/KR20240139085A/ko active Pending
- 2023-02-08 US US18/837,256 patent/US20250340659A1/en active Pending
- 2023-02-08 EP EP23706072.8A patent/EP4476256A1/en active Pending
- 2023-02-08 AU AU2023219227A patent/AU2023219227A1/en active Pending
- 2023-02-08 MX MX2024009898A patent/MX2024009898A/es unknown
- 2023-02-08 CA CA3258958A patent/CA3258958A1/en active Pending
- 2023-02-08 WO PCT/GB2023/050281 patent/WO2023152486A1/en not_active Ceased
-
2024
- 2024-08-07 CL CL2024002361A patent/CL2024002361A1/es unknown
- 2024-08-12 CO CONC2024/0010901A patent/CO2024010901A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250340659A1 (en) | 2025-11-06 |
| KR20240139085A (ko) | 2024-09-20 |
| IL314314A (en) | 2024-09-01 |
| CO2024010901A2 (es) | 2024-10-31 |
| MX2024009898A (es) | 2024-08-20 |
| JP2025506488A (ja) | 2025-03-11 |
| EP4476256A1 (en) | 2024-12-18 |
| CA3258958A1 (en) | 2023-08-17 |
| AU2023219227A1 (en) | 2024-08-01 |
| WO2023152486A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210323A1 (ar) | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 | |
| CO2021003036A2 (es) | Compuestos de anillo fusionado | |
| BR112021019334A2 (pt) | Anticorpos de cadeia pesada que se ligam ao psma | |
| DOP2024000207A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| JOP20220357A1 (ar) | ربط أجسام مضادة متعددة الخصوصية مع bcma | |
| JOP20230123A1 (ar) | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها | |
| CY1125025T1 (el) | 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης | |
| ECSP23025065A (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| MX2022010229A (es) | Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8). | |
| CO2023006684A2 (es) | Anticuerpos contra sars-cov-2 y usos de los mismos | |
| ECSP088613A (es) | Moléculas de anticuerpo que tienen especificidad para la il-6 humana | |
| BR112021025645A2 (pt) | Degradação de proteína alvo de parp14 para uso em terapia | |
| JOP20230109A1 (ar) | أجسام مضادة ثقيلة السلسلة ترتبط مع مستقبل ألفا فولات | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| MX2023009874A (es) | Anticuerpos anti-psma y estructuras car-t. | |
| CL2023003073A1 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
| BR112023020450A2 (pt) | Anticorpos anti-cd19 e estruturas car-t | |
| CL2025000063A1 (es) | Anticuerpos anti-abeta | |
| MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
| JOP20240132A1 (ar) | أجسام مضادة لـ c3 وشظايا ارتباط بمولد الضد منها واستخداماتها لعلاج العين أو الأمراض العينية | |
| CO2024010901A2 (es) | Anticuerpos terapéuticos | |
| MX2021011334A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| CL2025002201A1 (es) | Métodos de tratamiento de trastornos neurológicos con anticuerpos anti-abeta | |
| CL2022001684A1 (es) | Anticuerpo con especificidad de unión para il-13 humana | |
| BR112022013553A2 (pt) | Composição farmacêutica, anticorpo, e, método para tratar uma doença |